Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PPID | Q08752 | 2/20 | 0.32 |
| ▸ | PPIB | P23284 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | PPIG | Q13427 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19763309 | 1.00 | LOXL2 (0.34) | LOXL2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL19099646 | 0.94 | LOXL2 (0.39) | LOXL2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL19365160 | 0.92 | HDAC3 (0.30) | HDAC3HDAC1HDAC8HDAC6MAOA | |
| SCHEMBL15928040 | 0.86 | HDAC3 (0.35) | HDAC3HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL15928053 | 0.86 | HDAC3 (0.33) | HDAC3HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL22236838 | 0.86 | MEN1 (0.38) | HDAC3HDAC1HDAC8HDAC6EPHX1 | |
| SCHEMBL19084672 | 0.86 | ACHE (0.39) | LOXL2MAOAMAOBPPIDPPIB | |
| SCHEMBL15928051 | 0.86 | IDO1 (0.37) | MAOAMAOBCYP3A4TSHRTDP1 | |
| SCHEMBL15929442 | 0.83 | KDM4E (0.39) | LOXL2EPHX1HTTALDH1A1CYP3A4 | |
| SCHEMBL22236849 | 0.82 | HDAC3 (0.33) | HDAC3HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2026-04-23 | — | — | US | claimed |
| EP-4719494-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260069725-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Chengdu StarRay Therapeutics Co., Ltd (CN) | 2026-03-12 | — | — | US | claimed |
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms for Cure GmbH (DE) | 2026-02-19 | — | — | US | claimed |
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-11-18 | — | — | US | claimed |
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | UNIV JOHNS HOPKINS (US) | 2025-11-06 | — | — | US | claimed |
| US-12447217-B2 | Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2025-10-21 | — | — | US | claimed |
| US-20250288702-A1 | LABELING PRECURSORS WITH SQUARIC ACID COUPLING | Telix Pharmaceuticals Limited (AU) | 2025-09-18 | — | — | US | claimed |
| EP-4615521-A1 | KETO-AMIDE-BASED FIBROBLAST ACTIVATION PROTEIN-TARGETED LIGAND LINKED TO AN IMAGING OR THERAPEUTIC AGENT, COMPOSITIONS AND METHODS OF USE | Purdue Research Foundation (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2021123013-A1 | SMART DRUG DELIVERY SYSTEM AND PHARMACEUTICAL KIT FOR DUAL NUCLEAR MEDICAL CYTOTOXIC THERANOSTICS | Johannes Gutenberg-Universität Mainz (DE) | 2021-06-24 | — | — | WO | claimed |
| US-20200339625-A1 | NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-10-29 | — | — | US | claimed |
| WO-2020210909-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-10-22 | — | — | WO | claimed |
| EP-3206720-B1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2020-04-22 | — | — | EP | claimed |
| EP-3558395-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | The Johns Hopkins University (US) | 2019-10-30 | — | — | EP | claimed |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY | 2019-10-17 | — | — | US | claimed |
| WO-2018119313-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-28 | — | — | WO | claimed |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2017-11-16 | — | — | US | claimed |
| US-20080267882-A1 | Multimeric RGD (arginine-glycine-aspartic acid (Arg-Gly-Asp)) peptide; positron emission tomography; angiogenesis; kits | STANFORD UNIVERSITY (US) | 2008-10-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048156-A1 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | FAP, ALK, FIBP | LOXL2 1362/4885HDAC3 1525/4885HDAC1 1488/4885 |
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | TUBA3E, TUBB2A, ADCYAP1R1 | LOXL2 4739/4885HDAC3 927/4885HDAC1 1809/4885 |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | MUSK, TNNC1, TNNI3 | LOXL2 4020/4885HDAC3 1459/4885HDAC1 2696/4885 |
| US-20190314531-A1 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | CD274, PDCD1LG2, PDCD1 | LOXL2 1282/4885HDAC3 2507/4885HDAC1 3077/4885 |
| US-20200339625-A1 | NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | FOLH1, KLK3, PSMA3 | LOXL2 3542/4885HDAC3 2174/4885HDAC1 1910/4885 |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | PTH1R, VDR, MEN1 | LOXL2 2240/4885HDAC3 2128/4885HDAC1 1265/4885 |
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | KLK3, FOLH1, HRH3 | LOXL2 2185/4885HDAC3 1419/4885HDAC1 876/4885 |
| US-12447217-B2 | Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof | FAP, FIBP, FGFR1 | LOXL2 1799/4885HDAC3 2661/4885HDAC1 1314/4885 |
| US-20260069725-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, FOLH1 | LOXL2 2930/4885HDAC3 664/4885HDAC1 207/4885 |
| US-20250288702-A1 | LABELING PRECURSORS WITH SQUARIC ACID COUPLING | SCLY, SRRT, CS | LOXL2 4805/4885HDAC3 1895/4885HDAC1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.